drugset / Trial / NCT01518556
Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Phase 1/2
Completed
49 enrolled
Konkuk University Medical Center
Chonbuk National University Hospital · collabChung-Ang University Hospital · collabEwha Womans University · collabHanyang University Seoul Hospital · collabPusan National University Hospital · collabSamsung Medical Center · collabSeoul National University Hospital · collabSoon Chun Hyang University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether idarubicin dose intensification is safe and effective as a remission induction therapy for acute myeloid leukemia.
Timeline
- Start
- 2011-07
- Primary completion
- 2025-03
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 18 mg/m2 | Intravenous |